GPT and cancer: Therapeutic Targeting: ALT-related vulnerabilities (e.g., reliance on ATR, PARP, or homologous recombination) may be exploitable in ALT-positive cancers, but therapeutic efficacy will vary depending on whether ALT acts as a driver or a burden.